Lead Product(s) : Sodium Tungstate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Oxolife’s Oral Drug Increases IVF and ICSI Success Rates, Data Presented at ESHRE
Details : OXO-001 (sodium tungstate) is a first-in-class, non-hormonal drug that enhances embryo implantation. It is taken as a tablet twice daily, starting one menstrual cycle before embryo transfer.
Brand Name : OXO-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 08, 2024
Lead Product(s) : Sodium Tungstate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
